Tofacitinib experience in patients with enteropathic arthritis
Immunotherapy · 2023
DOI: 10.2217/imt-2022-0110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Pınar Akyüz Dağlı und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ankara City Hospital, Clinic of Rheumatology, Ankara, 06800, Turkey. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Spondylarthritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background/aim: The JAK-STAT pathway is involved in the pathogenesis of both the inflammatory bowel disease (IBD) and spondyloarthropathy group of diseases. The purpose of this study was to evaluate the effectiveness of tofacitinib, a Janus kinase inhibitor, in the treatment of enteropathic arthritis (EA). Materials & methods: The study included seven patients, four from the authors' follow-up and three from the literature. All cases were recorded for demographic characteristics, comorbidities, IBD and EA symptoms, medical treatments and changes in clinical and laboratory results with treatment. Results & conclusion: Clinical and laboratory remission in terms of IBD and EA was achieved in three patients after tofacitinib treatment. For both spondyloarthritis spectrum diseases and IBD, tofacitinib may be an appropriate choice, as its efficacy has been shown in both conditions. Tofacitinib, which inhibits the JAK enzyme, is an oral, nonbiologic, disease-modifying drug used in the treatment of rheumatologic diseases. Tofacitinib modulates the immune response and reduces or prevents inflammation. There are limited data on the efficacy of tofacitinib for the treatment of enteropathic arthritis. This study aimed to evaluate the efficacy of tofacitinib in the treatment of enteropathic arthritis. Seven patients, four from the authors' follow-up and three from the literature, were included in the study. All cases were recorded in terms of demographic characteristics, comorbidities, symptoms of inflammatory bowel disease and enteropathic arthritis, medical treatments and changes in treatment and clinical and laboratory results. After tofacitinib treatment, clinical and laboratory improvement was achieved in three patients. As a result, tofacitinib may be a suitable choice for enteropathic arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ankara City Hospital, Clinic of Rheumatology, Ankara, 06800, Turkey.
- Yıldırım Beyazıt University Medical School, Department of Internal Medicine, Division of Rheumatology, Ankara, 06800, Turkey.
- Ankara Yıldırım Beyazıt University Faculty of Medicine, Department of Internal Medicine Division of Gastroenterology, Ankara, 06800, Turkey.
- Ankara City Hospital, Clinic of Gastroenterology, Ankara, 06800, Turkey.
ORCID-Profile: Pınar Akyüz Dağlı, Serdar Can Güven, Berkan Armağan
Zitieren
APA
Dağlı, P. A., Erden, A., Güven, S. C., Armağan, B., Yürekli, Ö. T., Özin, Y. Ö., Omma, A., & Küçükşahin, O. (2023). Tofacitinib experience in patients with enteropathic arthritis. Immunotherapy. https://doi.org/10.2217/imt-2022-0110
Vancouver
Dağlı PA, Erden A, Güven SC, Armağan B, Yürekli ÖT, Özin YÖ, et al. Tofacitinib experience in patients with enteropathic arthritis. Immunotherapy. 2023. doi:10.2217/imt-2022-0110
BibTeX
@article{Dal2023,
author = {Dağlı, Pınar Akyüz and Erden, Abdulsamet and Güven, Serdar Can and Armağan, Berkan and Yürekli, Öykü Tayfur and Özin, Yasemin Özderin and Omma, Ahmet and Küçükşahin, Orhan},
title = {Tofacitinib experience in patients with enteropathic arthritis},
journal = {Immunotherapy},
year = {2023},
doi = {10.2217/imt-2022-0110}
}
EUVIMED